MRI gadolinium-based contrast agents. Radiologists beware!
Gadolinium (Gd) is used in contrast agents as it enhances magnetic resonance imaging (MRI) signals. To reduce Gd toxicity, it is chelated into linear or macrocyclic complexes. Eight Gd-containing contrast agents have been approved by the European Medicines Agency (EMEA) for use in MRI, and six by the US Food and Drug Administration. Stability depends upon its physicochemical properties. When renal function is normal, the Gd is quickly cleared from the body by the kidneys. For patients with chronic kidney disease, the elimination is greatly reduced and Gd may be released from its chelate and deposit in body tissues, leading to nephrogenic systemic fibrosis (NSF). More than 200 cases of NSF have been reported in the world. NSF is characterized by an extensive fibrosis of skin and tissues, a very severe affection with possible lethal outcome. We propose recommendations to avoid the risk of NSF.
Goullé
J-P
JP
Laboratoire de pharmacocinétique et de toxicologie cliniques, groupe hospitalier du Havre, BP 24, 76083 Le Havre cedex, France. jean-pierre.goulle@ch-havre.fr
Cattanéo
A
A
Saussereau
E
E
Mahieu
L
L
Guerbet
M
M
Lacroix
C
C
D002614:Chelating Agents; D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis; D005602:France / Q000453:epidemiology; D005682:Gadolinium / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000009:adverse effects*
D002614:Chelating Agents; D003287:Contrast Media; D005682:Gadolinium